StockNews.com Begins Coverage on Brooklyn ImmunoTherapeutics (NYSE:BTX)

Equities research analysts at StockNews.com assumed coverage on shares of Brooklyn ImmunoTherapeutics (NYSE:BTX) in a report released on Wednesday. The brokerage set a “hold” rating on the stock.

Brooklyn ImmunoTherapeutics Stock Down 3.0 %

Shares of BTX stock opened at $7.14 on Wednesday. The company has a 50 day moving average price of $1.21 and a 200-day moving average price of $1.12. The firm has a market capitalization of $420.02 million, a PE ratio of -3.15 and a beta of 4.61. Brooklyn ImmunoTherapeutics has a 52 week low of $6.66 and a 52 week high of $8.31.

Brooklyn ImmunoTherapeutics Company Profile

Eterna Therapeutics, Inc is a clinical stage biopharmaceutical company, which engages in creating transformative regenerative medicine treatments for cancer, blood disorders, and monogenic diseases. It offers IRX-2, a human cell-derived cytokine therapy, studying the safety and efficacy of IRX-2 in patients with head and neck cancer in Phase 2B.